BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Liver cancer AND TRA
50 results:

  • 1. [Analysis of the experience and procedural complications of trans-radial access versus trans-femoral access for hepatic arterial perfusion chemotherapy in patients with advanced hepatic malignancies:a retrospective study].
    Lyu TY; Li M; He JA; Sun QF; Wang L; Qin H; Yu HP
    Zhonghua Nei Ke Za Zhi; 2024 Feb; 63(2):183-191. PubMed ID: 38326045
    [No Abstract]    [Full Text] [Related]  

  • 2. Per-patient Negative Predictive Value of the CT and MRI liver Imaging Reporting and Data System Version 2018 Treatment Response Algorithm for Hepatocellular Carcinoma.
    Hassan OT; Behr SC; Ohliger MA; Fowler KJ; Gill RM; Fidelman N; Mehta N; Choi HH
    Radiology; 2023 Dec; 309(3):e222776. PubMed ID: 38112541
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. French Interventional Radiology Centers' Uptake of transradial Approach and Outpatient Hepatocellular Carcinoma Intra-Arterial Treatments.
    Grégory J; Ronot M; Laurent V; Chabrot P; de Baere T; Chevallier P; Vilgrain V; Aubé C;
    Cardiovasc Intervent Radiol; 2024 Apr; 47(4):432-440. PubMed ID: 37930400
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. transradial Access for transarterial Radioembolization (TARE) in Patients with Hepatocellular Carcinoma: Comparison with transfemoral Access.
    Yakupoğlu A; Buturak ÖSU
    Cardiovasc Intervent Radiol; 2023 Oct; 46(10):1359-1364. PubMed ID: 37723353
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Operator radiation exposure during radioembolisation of the liver: transfemoral versus transradial access using real-time dose monitoring.
    Pedersoli F; Fang J; Boas E; Park JJ
    Radiat Prot Dosimetry; 2023 Nov; 199(19):2344-2348. PubMed ID: 37644874
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Early post-treatment MRI predicts long-term hepatocellular carcinoma response to radiation segmentectomy.
    Stocker D; King MJ; Homsi ME; Gnerre J; Marinelli B; Wurnig M; Schwartz M; Kim E; Taouli B
    Eur Radiol; 2024 Jan; 34(1):475-484. PubMed ID: 37540318
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Updates on LI-RADS Treatment Response Criteria for Hepatocellular Carcinoma: Focusing on MRI.
    Patel R; Aslam A; Parikh ND; Mervak B; Mubarak E; Higgins L; Lala K; Conner JF; Khaykin V; Bashir M; Do RKG; Burke LMB; Smith EN; Kim CY; Shampain KL; Owen D; Mendiratta-Lala M
    J Magn Reson Imaging; 2023 Jun; 57(6):1641-1654. PubMed ID: 36872608
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Anti-VEGF and Anti-EGFR Antibody Therapy on T-Cell Infiltration and TCR Variation in Metastatic Colorectal cancer.
    Xu M; Tsunedomi R; Kiyotani K; Tomochika S; Furuya K; Nakajima M; Matsui H; Tokumitsu Y; Shindo Y; Yoshida S; Iida M; Suzuki N; Takeda S; Ioka T; Hazama S; Nagano H
    Anticancer Res; 2023 Feb; 43(2):613-620. PubMed ID: 36697107
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. transradial versus transfemoral access without closure device for transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized trial.
    Zhang X; Luo Y; Tsauo J; Zhao H; Gong T; Li J; Li Y; Zeng H; Sun W; Li X
    Eur Radiol; 2022 Oct; 32(10):6812-6819. PubMed ID: 36018356
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Operator radiation dose during trans-hepatic arterial chemoembolization: different patients' positions via transradial or transfemoral access.
    Jiang H; Chen Y; Liao H; Gu Y; Meng X; Dong W
    Diagn Interv Radiol; 2022 Jul; 28(4):376-382. PubMed ID: 35950283
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Optimal imaging criteria and modality to determine Milan criteria for the prediction of post-transplant HCC recurrence after locoregional treatment.
    Seo N; Joo DJ; Park MS; Kim SS; Shin HJ; Chung YE; Choi JY; Kim MS; Kim MJ
    Eur Radiol; 2023 Jan; 33(1):501-511. PubMed ID: 35821427
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. transradial versus transfemoral Access for Patients with liver cancer Undergoing Hepatic Arterial Infusion Chemotherapy: Patient Experience and Procedural Complications.
    Wan Y; Chen B; Li N; Yang JY; Dai HT; Tang KY; Wen CY; Huang YH
    J Vasc Interv Radiol; 2022 Aug; 33(8):956-963.e1. PubMed ID: 35500833
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. LI-RADS Treatment Response Algorithm: Performance and Diagnostic Accuracy With Radiologic-Pathologic Explant Correlation in Patients With SBRT-Treated Hepatocellular Carcinoma.
    Mendiratta-Lala M; Aslam A; Maturen KE; Westerhoff M; Maurino C; Parikh ND; Sun Y; Sonnenday CJ; Stein EB; Shampain KL; Kaza RK; Cuneo K; Masch W; Do RKG; Lawrence TS; Owen D
    Int J Radiat Oncol Biol Phys; 2022 Mar; 112(3):704-714. PubMed ID: 34644607
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Evaluation of the LI-RADS treatment response algorithm in hepatocellular carcinoma after trans-arterial chemoembolization.
    Kierans AS; Najjar M; Dutruel SP; Gavlin A; Chen C; Lee MJ; Askin G; Halazun KJ
    Clin Imaging; 2021 Dec; 80():117-122. PubMed ID: 34303189
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Evaluation of Hepatocellular Carcinoma Treatment Response After Locoregional Therapy.
    Kampalath R; Tran-Harding K; Do RKG; Mendiratta-Lala M; Yaghmai V
    Magn Reson Imaging Clin N Am; 2021 Aug; 29(3):389-403. PubMed ID: 34243925
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Imaging After Locoregional Therapy for Hepatocellular Carcinoma with Emphasis on LIRADS Treatment Response Assessment Criteria.
    Bajaj G; Sundaram K; Jambhekar K; Ram R
    Semin Ultrasound CT MR; 2021 Aug; 42(4):318-331. PubMed ID: 34130846
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. LI-RADS treatment response lexicon: review, refresh and resolve with emerging data.
    Ram R; Kampalath R; Shenoy-Bhangle AS; Arora S; Kielar AZ; Mendiratta-Lala M
    Abdom Radiol (NY); 2021 Aug; 46(8):3549-3557. PubMed ID: 34106301
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. LI-RADS Version 2018 Treatment Response Algorithm: Diagnostic Performance after transarterial Radioembolization for Hepatocellular Carcinoma.
    Yoon J; Lee S; Shin J; Kim SS; Kim GM; Won JY
    Korean J Radiol; 2021 Aug; 22(8):1279-1288. PubMed ID: 33987991
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Assessing locoregional treatment response to Hepatocellular Carcinoma: comparison of hepatobiliary contrast agents to extracellular contrast agents.
    Aslam A; Kamath A; Spieler B; Maschiocchi M; Sabottke CF; Chernyak V; Lewis SC
    Abdom Radiol (NY); 2021 Aug; 46(8):3565-3578. PubMed ID: 33856509
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Abbreviated MRI Protocol for the Assessment of Ablated Area in HCC Patients.
    Granata V; Grassi R; Fusco R; Setola SV; Belli A; Piccirillo M; Pradella S; Giordano M; Cappabianca S; Brunese L; Grassi R; Petrillo A; Izzo F
    Int J Environ Res Public Health; 2021 Mar; 18(7):. PubMed ID: 33808466
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 3.